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KEY INSIGHTS 
1. Distribution of pharmaceutical in sub-Saharan
Africa is poorly understood and perceived as
risky business.
2. Improved knowledge of pharmaceutical supply
chains can result in better distribution coverage
and access to medicines.
3. Adoption of appropriate distribution strategies
can improve availability and affordability of
medicines  in sub-Saharan Africa
Introduction 
Traditionally, large multi-national pharmaceutical 
companies perceived Africa as a small risky market. 
However, in the recent years there has been 
growing interest in serving markets in sub Saharan 
Africa. This renewed interest appears to come from 
two reasons namely, the future business potential 
for these markets is large and secondly, by so doing, 
it signals good corporate citizenship for the multi-
national pharmaceutical companies.  
However, the limited ability of countries in sub 
Saharan Africa to pay and the inconsistent flow of 
funds from donor agencies further intensify the 
perceived riskiness of the sub-Saharan African 
markets. Further, lack of effective supply chains is 
considered a key reason for the slow materialization 
of demand in these markets. 
Strong supply chains are essential to effective health 
care delivery in all sectors - public, faith-based1, and 
private. However, the process through which a 
particular medicine or drug flows through the supply 
chain from the manufacturer to the patients in sub-
Saharan Africa has not been well documented. This 
paucity of knowledge is a bottleneck to access of 
essential and life-saving pharmaceutical products to 
patients in this region.  
An extensive review of literature (32 references 
distributed across 12 developing countries) on retail 
sector distribution chains for malaria treatment in 
developing world published in Malaria Journal 
(February 2010) concluded that evidence on the 
distribution chain for retail sector malaria treatment 
was mainly descriptive and lacked representative 
data on a national scale. Documenting the process 
and the associated challenges will therefore provide 
the necessary insights to guide supply chain 
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strategies for manufacturers who view Africa as an 
important emerging market for pharmaceuticals. 
This thesis was an attempt to find the right supply 
chain strategy for a large pharmaceutical company 
to improve access to its medicines in sub Saharan 
Africa.   
 
Pharmaceutical Supply Chains in Africa  
 
Pharmaceutical markets in other parts of the world 
including the Middle East and North Africa currently 
differ significantly from markets in sub-Saharan 
Africa. Even within sub-Saharan Africa, there are 
significant differences between Anglophone and 
Francophone countries, with the differences being 
more pronounced in the regulatory area of 
pharmaceutical supply chains. This study focused 
on sub-Saharan Africa, where an in-depth study of 
Kenya was carried out to represent East African 
markets. A study of Ghana was also done and 
findings reported in a separate report. 
Figure 1 below shows a typical pharmaceutical 
product value chain from product development to 
point of healthcare delivery.  
 
 
Figure 1 Pharmaceutical product value chain 
 
Access to medicines in sub-Saharan Africa 
 
Essential medicines save lives and improve people’s 
health when they are available, affordable, of 
assured quality and properly used. Figure 2 shows 
key factors affecting access to essential medicines.  
According to Yadav et al (2009), uptake of malaria 
medicines is a real problem in malaria endemic 
countries due to challenges prevalent at the lower 
level (downstream) supply chain. These include 
bottlenecks at the drug regulatory authorities, lack of 
appropriate supply chain coordination and poor 
physical infrastructure. This is confirmed by the 
findings of this study which show that access to 
essential medicines remains low in Kenya, 
especially in rural areas and resource limited 
settings such as slums in the capital city. There is 
low availability and affordability of medicines due to 
low purchasing power, poor road network and lack 
of proper distribution channels and facilities.   
Literature reviewed shows an increasing role of 
private sector in improving access to medicines but 
clearly points to a glaring knowledge gap in supply 
chain strategies to achieve effective distribution of 
pharmaceutical products in sub-Saharan Africa.  
 
 
Figure 2 Factors affecting uptake of malaria 
medicines (Yadav, Stapleton, & Wassenhove, 2009) 
 
In-country distribution of pharmaceuticals  
 
In-country distribution is achieved through three key 
distribution systems namely; public, private-for-profit 
and private-not-for-profit systems (see figure 3).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 Interaction between private and public 
sector distribution systems (Adopted from Yadav, 
Stapleton, & Wassenhove, 2009) 
 
Distribution channel options in Kenya 
 
Current distribution channel options in Kenya can be 
classified into four main categories based on their 
competitive strategies. These are retail chains, 
niches, logistics service providers and “middle of the 
road” distributors.  
Drug Manufacturers Procurement Agents 
Manufacturers National 
Representative 
Distributors 
Regional Medical Stores/ 
Regional Hospitals 
Private Prescribers Sub-wholesalers
Importers/ Wholesalers 
Central Medical 
Store
Second Tier Pharmacies/ 
Chemists 
District Medical Stores/ 
District Hospitals 
Patients 
Community 
Health Workers 
Health Center 
Pharmacies
PUBLIC SECTOR
International
   National
Regional 
  District 
City & Towns 
Small Town/ Rural 
Community 
PRIVATE SECTOR 
Retail chains have centralized procurement units 
through which they purchase inventory as 
wholesalers and distribute to end-users (patients) 
through a network of retail pharmacies. Niche 
distributors operate a distribution system that is 
designed to serve a well defined niche market 
segment. They include distributors in public sector 
(central medical stores), faith-based sector (MEDS) 
and franchise shops run by humanitarian 
organizations (e.g. CFW Shops). They have a 
centralized procurement unit to facilitate bulk 
purchases and hence get competitive prices.  
 
Distribution using logistics service providers (LSP) is 
a new concept in Kenya. Most provide warehousing 
and distribution services on behalf of the 
manufacturer in return for a commission. Middle of 
the road distributors are those without a clearly 
defined distribution strategy and do a little of each of 
the components of supply chain operations. They 
import, distribute, wholesale and some also run retail 
chains.  
 
Distribution challenges & risks in Kenya 
 
The following are the key challenges facing 
distribution of pharmaceuticals in Kenya:  
Undercapitalization: healthcare outlets in resource 
limited settings lack adequate working capital. 
Because of the nature of their small scale 
operations, they have limited chances of attracting 
credit from the distributors or banks who regard 
them as risky customers.  
Foreign exchange fluctuations: Local currency 
fluctuations against the dollar are a challenge to 
maintenance of steady product prices for a long time 
even when the prices have remained stable from the 
manufacturer. This results in foreign exchange 
losses incurred by the importers every time they 
place a new order. 
Poor debt management: Weak legal systems, poor 
vetting of credit customers and lack of debt 
management skills are responsible for bad debts 
and delays in collection of receivables. 
Grey markets and trade in counterfeit 
pharmaceuticals: Grey market and trade in 
counterfeit pharmaceuticals is associated with 
serious negative impact on business and health 
outcomes of the patients. Grey markets thrive in 
Kenya due to high price differentials and supply 
inadequacy within the market. 
Low purchasing power: The purchasing power of 
majority of people living in Kenya is low with most 
families paying for health services as out-of-pocket 
expenses. 
Uncertainty of in-market demand: Demand 
uncertainty and lack of appropriate forecasting skills 
result in losses through products expiries, loss of 
revenue and goodwill due to stock-outs and hence 
diminished profitability arising from price mark-
downs to clear short dated products. 
 
 
 
Recommendations to improve distribution of 
pharmaceuticals in Kenya 
 
In light of the risks and challenges identified in 
Kenya, the following five recommendations have 
been proposed as mitigation measures from a 
manufacturer’s perspective. They can also be 
applied other sub-Saharan markets. 
 
Establishment of regional distribution centers 
(RDCs): Use of RDCs is expected to result in better 
economies of scale and scope because the hub can 
order large quantities and varieties of products from 
the manufacturer to satisfy the demand in the entire 
region. This will further lead to lower foreign 
exchange risks resulting from less frequent orders 
from the overseas manufacturer thereby resulting in 
stable prices. Use of RDC would also result in 
reduction of in-country lead times due to stock 
stability at the hub and relatively shorter distances 
between the hub and the in-country markets.  
Benefits of establishing a RDC are summarized 
below (see table 1). 
 
Benefit  Explanation 
Increase  
products security 
 
Closely track the chain of 
inventory custody to control 
grey markets and introduction 
of counterfeit products in the 
supply chains  
 
Lower cost of in-
bound logistics  
 
Lower unit costs of 
commodities and shipping 
obtained from “pooling” 
procurement and consolidating 
shipments for the region. 
Consolidate a number of 
products into a single 
shipment, thus reducing costs 
and time of administration and 
processes such as customs 
clearance. 
Lower foreign 
exchange risks & 
Price stability 
Less frequent orders from 
manufacturer hence lower 
foreign exchange losses 
leading to price stability 
Lower cost of  in-
country 
distribution and  
lower working 
capital 
requirements 
(out-bound 
logistics) 
Shift inventory storage to a 
nearby location where in-
country supplies can be drawn 
in smaller quantities on need 
basis  
Shorter lead-times hence 
lower inventory holding 
requirements and lower overall 
distribution costs. Smaller and 
more frequent shipments 
enable in-country supply 
chains to increase throughput.  
Table 1 Benefits of using RDC 
 
Establishment of a credit financing mechanism 
for rural pharmacies and drug shops: Innovative 
financing mechanisms initiated by the manufacturer, 
such as drug shop credit financing using community 
approaches and use of mobile telephone money 
transfer services (e.g. M-Pesa) would result in 
improved availability of working capital to 
pharmaceutical outlets operating below the level of 
distributors and especially those in rural areas and 
other resource limited settings. This will in turn result 
in improved geographical coverage and better 
access.  
 
Differential pricing: Differential pricing is a strategy 
which involves charging two different prices for the 
same product but in different market segments 
based on their purchasing power. If properly applied, 
it can be a strong incentive to encourage increased 
products uptake, higher market coverage and 
product penetration.  
 
Establishment of strategic partnerships: A 
manufacturer can increase product availability and 
affordability through establishment of partnership 
with distributors and stakeholders who are already 
serving customers in the target market segments. By 
so doing, the manufacturer will benefit from utilizing 
the distributor’s established distribution channels, 
market knowledge and goodwill. 
 
Ensure ownership of in-country marketing 
authorization rights: Whenever a firm cedes its 
products marketing authorization to a third party 
such as an agent or distributor, it loses flexibility to 
appoint multiple distributors or change the agent 
who holds the rights in a particular country. Thus in 
order to allow for flexibility in organizing distribution 
system in each country and to achieve desired 
outcomes, the pharmaceutical firm should consider 
taking control of marketing authorization rights.  
 
Implementation of these strategic options is 
expected to result in supply chain systems that 
promote wide distribution coverage, better prices to 
patients and overall profitability of all the 
stakeholders in the supply chain.   
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